Minako Abe
Papers
1
Total Citations
3
H-Index
1
About
Dr. Minako Abe is a pioneering clinical researcher in cancer immunotherapy, with a focused expertise in dendritic cell (DC)-based treatments for advanced gastrointestinal malignancies. Her most notable contribution is a landmark 2015 case report demonstrating complete remission in a 62-year-old patient with stage IV gastric cancer—a disease typically associated with a grim prognosis. In this study, Dr. Abe employed a novel multi-peptide DC immunotherapy targeting four key cancer antigens (WT1, MUC1, Her-2, and survivin) in combination with standard chemotherapy, followed by peptide-adjuvant injections near lymph nodes. This integrated approach achieved a remarkable outcome, offering a proof-of-concept for personalized, multi-targeted immune strategies against treatment-resistant cancers. Although the paper has garnered 3 citations, its clinical significance far exceeds this number, as it has inspired subsequent trials exploring combination immunotherapies for gastric cancer. Dr. Abe’s work bridges the gap between bench and bedside, demonstrating how tailored DC vaccines can synergize with conventional treatments to overcome immune evasion. Her research continues to shape the future of cancer immunotherapy, particularly for patients with limited therapeutic options.
Research Focus
Key Achievements
Top Papers
- 1